Evaluation of Bone Biomarkers in Renal Osteodystrophy

Area of Science:

• Nephrology
• Endocrinology
• Bone Metabolism

Background:

• Renal osteodystrophy (ROD) involves histological bone changes in chronic kidney disease (CKD) patients.
• ROD is classified by bone turnover (low/high) and mineralization defects.
• Bone histomorphometry is the gold standard but not widely accessible.

Purpose of the Study:

• To evaluate bone biomarkers for discriminating turnover and mineralization defects in hemodialysis (HD) patients.
• To assess the utility of various biomarkers including alkaline phosphatase (AP), parathyroid hormone (PTH), and others.
• To establish practical methods for ROD assessment in clinical settings.

Main Methods:

• Cross-sectional study of 32 HD patients.
• Collected bone biomarkers: BSAP, tAP, P1NP, CTX, iPTH, wPTH, SOST, FGF-23, vitamin D, OPG, RANKL.
• Bone histomorphometry used for classification of turnover and mineralization defects.

Main Results:

• Mineralization defects, low turnover, and high turnover identified in 47%, 50%, and 41% of patients, respectively.
• Bone biomarkers (tAP, BSAP, CTX, P1NP) and hormones (iPTH, wPTH, SOST) effectively identified low and high turnover (AUC > 0.857, p < 0.001).
• Lower calcium levels (< 8.7 mg/dL) correlated with mineralization defects; FGF-23, OPG, and RANKL showed no impact.

Conclusions:

• Bone biomarkers (BSAP, P1NP, PTH) and calcium levels can assess turnover and mineralization defects in HD patients.
• These biomarkers provide a viable alternative to bone histomorphometry for ROD assessment.
• Utilizing bone biomarkers can guide ROD and osteoporosis treatment and monitoring in CKD patients.